Geocann and Nestlé Health Science (Nestlé) have announced the European launch of CBD (from broad spectrum hemp extract) soft gel formulations using the patented VESIsorb drug delivery system. The first large-scale production was completed and delivered earlier this month using only European resources, from the cultivation and extraction of the hemp biomass in Slovenia to the drug delivery technology and soft gel capsule production in Switzerland.
“We are extremely proud to expand our relationship with Nestlé’s healthcare professional brands into Europe after their success in the US market this past year,” said Jesse Lopez, CEO and founder of Geocann. “Their leadership team’s validation of science-backed and clinically-proven hemp products is an important milestone for our industry and provides exceptional credibility to the therapeutic benefits of cannabinoids formulated with VESIsorb.”
Overall, the VESIsorb formulation showed statistically significant improvements for all measured pharmacokinetic parameters
VESIsorb is a naturally self-assembling colloidal droplet delivery system. The peer-reviewed journal, Molecules, published the results of a double-blind, cross-over design study comparing the pharmacokinetic (PK) parameters of a broad spectrum hemp extract formulated with VESIsorb to that of the same broad spectrum hemp extract combined with medium chain triglyceride (MCT) oil.
Overall, the VESIsorb formulation showed statistically significant improvements for all measured pharmacokinetic parameters, including maximal plasma CBD concentration (Cmax), area under the curve (AUC) and time to peak absorption (Tmax). The complete manuscript can be accessed on Geocann’s website.
Dr Barry Ritz, Chief Science Officer at Pure Encapsulations said: “Together with Geocann, we share a passion and commitment to product safety, purity, and performance. Our partnership is built on a relentless effort to ensure these are the most science-backed CBD products in the world, setting the benchmark for what consumers expect and healthcare professionals demand.”
According to Lopez, in addition to recent PK studies and the stability data for its products, further investments in clinical research focused on both PK performance and clinical end points are well under way. Additionally, multiple toxicology studies have been completed and will be published this year as part of the Geocann’s FDA GRAS (Generally Regarded As Safe) Notification and Novel Food application.